Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BD200 in Advanced Solid Tumors
NCT07797907Phase 1Not yet recruiting
- Sponsor
- Biolojic Design
- Start
- Dec 2026
- Primary completion
- Dec 2028
01
Overview
Phase 1, open-label trial of BD200 in solid tumor (2 arms), sponsored by Biolojic Design. Primary endpoint: Incidence of Adverse Events and Dose-Limiting Toxicities at 12 months. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
BD200
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07797907.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07797907.